UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study

Journal of clinical oncology, 2016-03, Vol.34 (7), p.661-668

2016

Volltextzugriff (PDF)

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2013-11, Vol.31 (32), p.4105-4114

2013

Volltextzugriff (PDF)

Positron Emission Tomography in Limited-Stage Small-Cell Lung Cancer: A Prospective Study

Journal of clinical oncology, 2004-08, Vol.22 (16), p.3248-3254

2004

Volltextzugriff (PDF)

Sotorasib plus carboplatin and pemetrexed in KRAS G12C advanced NSCLC: Updated analysis from the international CodeBreaK 101 trial

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.8512-8512

2024

Volltextzugriff (PDF)

Trial in progress: A phase 1b study of sotorasib, a specific and irreversible KRAS G12C inhibitor, as monotherapy in non-small cell lung cancer (NSCLC) with brain metastasis and in combination with other anticancer therapies in advanced solid tumors (CodeBreaK 101)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS2669-TPS2669

2021

Volltextzugriff (PDF)

Phase II Trial of Bexarotene Capsules in Patients With Advanced Non–Small-Cell Lung Cancer After Failure of Two or More Previous Therapies

Journal of clinical oncology, 2006-10, Vol.24 (30), p.4848-4854

2006

Volltextzugriff (PDF)

A phase III study of pemetrexed (Pem) plus carboplatin (Cb) plus bevacizumab (Bev) followed by maintenance pem plus bev versus paclitaxel (Pac) plus cb plus bev followed by maintenance bev in stage IIIb or IV nonsquamous non-small cell lung cancer (NS-NSCLC): Overall and age group results

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.8004-8004

2013

Volltextzugriff (PDF)

Randomized phase III trial of pemetrexed (Pem)+carboplatin (Cb)+bevacizumab (Bev) followed by maintenance Pem+Bev (Pem arm) versus paclitaxel (Pac)+Cb+Bev followed by maintenance Bev (Pac arm) in patients (pts) with stage IIIb/IV nonsquamous non-small cell lung cancer (nsNSCLC) (POINTBREAK): African American (AA) subset

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.e19150-e19150

2013

Volltextzugriff (PDF)

Exploratory analyses of efficacy and safety of pemetrexed (Pem) plus bevacizumab (Bev) and bev alone as maintenance therapy (MT) in patients (Pts) with stage IIIb or IV nonsquamous non-small cell lung cancer (NS-NSCLC)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.8012-8012

2013

Volltextzugriff (PDF)

Phase II study of pemetrexed (P) plus carboplatin (Cb) or cisplatin (C) with concurrent radiation therapy followed by pemetrexed consolidation in patients (pts) with favorable-prognosis inoperable stage IIIA/B non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.7002-7002

2012

Volltextzugriff (PDF)

Translational research (TR) results from pointbreak: A randomized, open-label, phase III study of pemetrexed (Pem)+carboplatin (Cb)+bevacizumab (Bev) followed by maintenance pem+bev (Pem Arm) versus paclitaxel (Pac)+cb+bev followed by maintenance bev (Pac Arm) in patients (pts) with stage IIIB or IV nonsquamous non-small cell lung cancer (ns-NSCLC)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.8086-8086

2013

Volltextzugriff (PDF)

Patient-reported outcomes from POINTBREAK: The randomized, open-label, phase III study of pemetrexed (pem) + carboplatin (cb) + bevacizumab (bev) followed by maintenance pem + bev versus paclitaxel (pac) + cb + bev followed by maintenance bev in patients with stage IIIb or IV nonsquamous non-small cell lung cancer (NS-NSCLC)

Journal of clinical oncology, 2012-12, Vol.30 (34_suppl), p.53-53

2012

Volltextzugriff (PDF)

A prospective study on the incidence of delayed nausea and vomiting following administration of carboplatin-containing regimens for treatment of cancer without prophylactic aprepitant

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e19552-e19552

2010

Volltextzugriff (PDF)

Prognostic impact of malignant pleural effusion in patients with stage M1b non-small cell lung cancer

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.7636-7636

2010

Volltextzugriff (PDF)

Distinctive characteristics of non-small cell lung cancer in the young: A SEER analysis of patients under 40 years old

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.7621-7621

2007

Volltextzugriff (PDF)

The SELECT trial: A multicenter phase II trial of adjuvant erlotinib (E) in patients with resected, early-stage non-small cell lung cancer (NSCLC) and confirmed mutations in the epidermal growth factor receptor (EGFR)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.TPS209-TPS209

2011

Volltextzugriff (PDF)

Ongoing phase II study of pemetrexed plus carboplatin or cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/b non-small cell lung cancer: Interim update

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.7082-7082

2010

Volltextzugriff (PDF)

Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.7505-7505

2011

Volltextzugriff (PDF)

Epithelial-mesenchymal transition and brain metastasis in non-small cell lung cancer

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.19027-19027

2008

Volltextzugriff (PDF)

Distinctive characteristics of extrapulmonary small cell carcinoma: A Surveillance Epidemiology and End Results (SEER) analysis

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.22106-22106

2008

Volltextzugriff (PDF)

Non-small cell lung cancer in the new millennium: The effect of FDG-PET on stage distribution

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.7205-7205

2006

Volltextzugriff (PDF)

An open label phase II trial of the Plk1 inhibitor BI 2536, in patients with sensitive relapse small cell lung cancer (SCLC)

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.8108-8108

2009

Volltextzugriff (PDF)

A prospective study on the incidence of delayed nausea and vomiting following administration of carboplatin containing regimens for treatment of cancer without prophylactic aprepitant

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.20626-20626

2008

Volltextzugriff (PDF)

Use of the internet for self-education by adults with cancer

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.6606-6606

2008

Volltextzugriff (PDF)

1 – 25 von 48

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Clinical Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(48)
Mit Volltextzugriff
(47)

Publikationsform

Artikel
(48)

Sprache

Erscheinungsjahr

n.n

Thema

Aged
(5)
Female
(5)
Humans
(5)
Male
(5)
Middle Aged
(5)
Adult
(4)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(4)
Life Sciences & Biomedicine
(4)
Lung Neoplasms - Drug Therapy
(4)
Lung Neoplasms - Pathology
(4)
Oncology
(4)
Science & Technology
(4)
Aged, 80 And Over
(3)
Biological And Medical Sciences
(3)
Carcinoma, Non-Small-Cell Lung - Pathology
(3)
Medical Sciences
(3)
Pneumology
(3)
Treatment Outcome
(3)
Tumors
(3)
Tumors Of The Respiratory System And Mediastinum
(3)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

1 weiteren anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

Positron Emission Tomography in Limited-Stage Small-Cell Lung Cancer: A Prospective Study

Sotorasib plus carboplatin and pemetrexed in KRAS G12C advanced NSCLC: Updated analysis from the international CodeBreaK 101 trial

Trial in progress: A phase 1b study of sotorasib, a specific and irreversible KRAS G12C inhibitor, as monotherapy in non-small cell lung cancer (NSCLC) with brain metastasis and in combination with other anticancer therapies in advanced solid tumors (CodeBreaK 101)

Phase II Trial of Bexarotene Capsules in Patients With Advanced Non–Small-Cell Lung Cancer After Failure of Two or More Previous Therapies

A phase III study of pemetrexed (Pem) plus carboplatin (Cb) plus bevacizumab (Bev) followed by maintenance pem plus bev versus paclitaxel (Pac) plus cb plus bev followed by maintenance bev in stage IIIb or IV nonsquamous non-small cell lung cancer (NS-NSCLC): Overall and age group results

Exploratory analyses of efficacy and safety of pemetrexed (Pem) plus bevacizumab (Bev) and bev alone as maintenance therapy (MT) in patients (Pts) with stage IIIb or IV nonsquamous non-small cell lung cancer (NS-NSCLC)

Phase II study of pemetrexed (P) plus carboplatin (Cb) or cisplatin (C) with concurrent radiation therapy followed by pemetrexed consolidation in patients (pts) with favorable-prognosis inoperable stage IIIA/B non-small cell lung cancer (NSCLC)

A prospective study on the incidence of delayed nausea and vomiting following administration of carboplatin-containing regimens for treatment of cancer without prophylactic aprepitant

Prognostic impact of malignant pleural effusion in patients with stage M1b non-small cell lung cancer

Distinctive characteristics of non-small cell lung cancer in the young: A SEER analysis of patients under 40 years old

The SELECT trial: A multicenter phase II trial of adjuvant erlotinib (E) in patients with resected, early-stage non-small cell lung cancer (NSCLC) and confirmed mutations in the epidermal growth factor receptor (EGFR)

Ongoing phase II study of pemetrexed plus carboplatin or cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/b non-small cell lung cancer: Interim update

Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC

Epithelial-mesenchymal transition and brain metastasis in non-small cell lung cancer

Distinctive characteristics of extrapulmonary small cell carcinoma: A Surveillance Epidemiology and End Results (SEER) analysis

Non-small cell lung cancer in the new millennium: The effect of FDG-PET on stage distribution

An open label phase II trial of the Plk1 inhibitor BI 2536, in patients with sensitive relapse small cell lung cancer (SCLC)

A prospective study on the incidence of delayed nausea and vomiting following administration of carboplatin containing regimens for treatment of cancer without prophylactic aprepitant

Use of the internet for self-education by adults with cancer

Aktive Filter

Suchergebnisse filtern